Hostname: page-component-cd9895bd7-dk4vv Total loading time: 0 Render date: 2024-12-25T06:00:34.180Z Has data issue: false hasContentIssue false
  • English
  • Français

HEALTH TECHNOLOGY ASSESSMENT IN CENTRAL, EASTERN, AND SOUTH EUROPEAN COUNTRIES: CROATIA

Published online by Cambridge University Press:  14 August 2017

Mirjana Huic ,
Romana Tandara Hacek  and
Ivan Svajger
Mirjana Huic
Affiliation:
Agency for Quality and Accreditation in Health Care and Social Welfare, Department for Development, Research and Health Technology [email protected]
Romana Tandara Hacek
Affiliation:
Agency for Quality and Accreditation in Health Care and Social Welfare, Department for Development, Research and Health Technology Assessment
Ivan Svajger
Affiliation:
Agency for Quality and Accreditation in Health Care and Social Welfare, Department for Development, Research and Health Technology Assessment
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives: The aim of this study was to provide a brief, 7-year history of health technology assessment (HTA) implementation in Croatia through national and international activities.

Methods: We used retrospective descriptive analysis of key documents related to the legal framework, process of decision making, and HTA. Analysis of the Agency's plan for and experience with the implementation of a transparent HTA process in Croatia was performed by addressing seven key components of the HTA implementation scorecard framework. The main challenges and facilitating factors were also assessed.

Results: HTA is not yet fully implemented in Croatia. The main challenges are the insufficient legal framework, limited human and financial resources, and limited stakeholder involvement. Facilitating factors are active international collaboration and education through EUnetHTA and the International Society for Pharmacoeconomics and Outcomes Research and production of national and international HTA reports.

Conclusions: The HTA process is not yet sustainable in Croatia and HTA reports are still not mandatory for reimbursement/investment or disinvestment decision processes. There are still barriers to overcome.

Keywords

Health technology assessmentCroatiaAgency for Quality and Accreditation in Health Care and Social WelfareCollaboration
Type
Theme Submissions
Information
International Journal of Technology Assessment in Health Care , Volume 33 , Issue 3: Theme: HTA in Central-Eastern-Southern Europe , 2017 , pp. 376 - 383
Copyright
Copyright © Cambridge University Press 2017 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1. Džakula, A, Sagan, A, Pavić, N, Lončarek, K, Sekelj-Kauzlarić, K. Croatia: Health system review. Health Syst Transit. 2014;16:1–162.Google ScholarPubMed
2. World Health Organization. 2013. http://www.who.int/countries/hrv/en/ (accessed January 11, 2016).Google Scholar
3. HZZO Godišnje izvješće za 2014. godinu, Zagreb, veljača 2015. Croatian Health Insurance Fund Annual report 2014. http://cdn.hzzo.hr/wp-content/uploads/2015/06/financijsko_izvjesce_2014.pdf (accessed January 11, 2016).Google Scholar
4. Croatian Bureau of Statistics. http://www.dzs.hr/, http://www.dzs.hr/default_e.htm (accessed January 11, 2016).Google Scholar
5. HZZO Godišnje izvješće za 2013. godinu, Zagreb, svibanj 2014. Croatian Health Insurance Fund Annual report 2013. http://cdn.hzzo.hr/wp-content/uploads/2014/05/HZZO_izvjesce_2013_KB_FINAL.pdf (accessed January 11, 2016).Google Scholar
6. Government of the Republic of Croatia Ministry of Health of the Republic of Croatia. National Health Care Strategy 2012–2020, Abridged version, September 2012. Zagreb: Croatia Ministry of Health.Google Scholar
7. Kaló, Z, Gheorghe, A, Huic, M, Csanádi, M, Kristensen, FB. HTA Implementation roadmap in central and eastern European countries. Health Econ. 2016;25 (Suppl 1):179–192.Google Scholar
8. Agency for Quality and Accreditation in Health Care, Department for Development, Research and Health Technology Assessment. The Croatian Guideline for Health Technology Assessment Process and Reporting, 1st ed Zagreb, February 2011. http://www.aaz.hr/main.php?ID=21 (accessed January 11, 2016).Google Scholar
9. Zechmeister, I., Huić, M. (2011): Vascular-Endothelial-Growth-Factor-Inhibitors (anti-VEGF) in the Management of Diabetic Macular Oedema. English version. Decision Support Document 43. http://eprints.hta.lbg.ac.at/917/ (accessed January 11, 2016).Google Scholar
10. Huić, M. Transkateterska implantacija aortne valvule (engl. Transcatheter Aortic Valve Implantation-TAVI): Procjena zdravstvene tehnologije (engl. HTA), Broj 01/2012. Agencija za kvalitetu i akreditaciju u zdravstvu i socijalnoj skrbi, Odjel za razvoj, istraživanje i zdravstvene tehnologije. Zagreb, veljača 2012. http://aaz.hr/sites/default/files/hta_01_2012.pdf (accessed January 11, 2016).Google Scholar
11. Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011 on the application of patients’ rights in cross-border healthcare. http://eur-lex.europa.eu/legal-content/EN/TXT/HTML/?uri=URISERV:sp0002&rid=1 (accessed December 29, 2015).Google Scholar
12. Commission Implementing Decision of 26 June 2013 providing the rules for the establishment, management and transparent functioning of the Network of national authorities or bodies responsible for health technology assessment. Official Journal of the European Union L 175/71. http://ec.europa.eu/health/technology_assessment/docs/impl_dec_hta_network_en.pdf (accessed December 29, 2015).Google Scholar
13. Strategy paper for EU cooperation on HTA; Adopted by the HTA network, 29 October 2014. http://ec.europa.eu/health/technology_assessment/docs/2014_strategy_eucooperation_hta_en.pdf (accessed December 29, 2015).Google Scholar
14. Reflection paper on Reuse of Joint Work in national HTA activities Adopted by the HTA network, 15 April 2015. http://ec.europa.eu/health/technology_assessment/docs/reuse_jointwork_national_hta_activities_en.pdf (accessed December 29, 2015).Google Scholar
15. 67 World Health Assembly Resolution: Health intervention and technology assessment in support of universal health coverage, 2014. http://apps.who.int/gb/ebwha/pdf_files/WHA67/A67_R23-en.pdf (accessed December 29, 2015).Google Scholar
16. Jacob, R, McGregor, M. Assessing the impact of health technology assessment. Int J Technol Assess Health Care. 1997;13:68- 80.Google Scholar
17. Schumacher, I, Zechmeister, I. Auswirkungen der HTA-Forschung auf das Gesundheitswesen in Ȍsterreich. Teil 2. Ergebnisse der empirischen Erhebung. HTA-Projektbericht Nr. 37b. 2011. Wien: Ludwig Boltzmann Institut fur Health Technology Assessment.Google Scholar
18. Zechmeister, I, Schumacher, I. The impact of health technology assessment reports on decision making in Austria. Int J Technol Assess Health Care. 2012;28:77–84.Google Scholar
19. Guthrie, S, Bienkowska-Gibbs, T, Manville, C, Pollitt, A, Kirtley, A, Wooding, S. The impact of the National Institute for Health Research Health Technology Assessment programme, 2003–13: A multimethod evaluation. Health Technol Assess. 2015;19:1–291.CrossRefGoogle ScholarPubMed
20. Huić, M. Radioterapija tumora česticama (snopom protona, ugljikovih iona, iona helija ili drugim česticama) (engl. Particle Beam Radiation Therapies for Cancer: HTA): Procjena zdravstvene tehnologije (engl. HTA), Broj 05/2013. Agencija za kvalitetu i akreditaciju u zdravstvu i socijalnoj skrbi, Služba za razvoj, istraživanje i zdravstvene tehnologije. Zagreb, lipanj 2013.). http://aaz.hr/sites/default/files/hta_05_2013.pdf (accessed January 11, 2016).Google Scholar
21. Huić, M, Tandara Haček, R. Sofosbuvir u liječenju bolesnika s kroničnim hepatitisom C (engl. Sofosbuvir for treating chronic hepatitis C): Procjena zdravstvene tehnologije (engl. HTA), Broj 13/2015. Agencija za kvalitetu i akreditaciju u zdravstvu i socijalnoj skrbi, Služba za razvoj, istraživanje i zdravstvene tehnologije. Zagreb, lipanj 2015. http://aaz.hr/sites/default/files/HTA_13_2015.pdf (accessed January 11, 2016).Google Scholar
22. Tandara Haček, R. Lijekovi za liječenje odraslih muškaraca s hormonski rezistentnim metastatskim karcinomom prostate (engl. Drugs for treating adult men with hormone resistant metastatic prostate cancer): Procjena zdravstvene tehnologije (engl. HTA), Broj 15/2015. Agencija za kvalitetu i akreditaciju u zdravstvu i socijalnoj skrbi, Služba za razvoj, istraživanje i zdravstvene tehnologije. Zagreb, lipanj 2015. http://aaz.hr/sites/default/files/HTA_15_2015.pdf (accessed January 11, 2016).Google Scholar
23. Huić, M, Tandara Haček, R, Boban, M. Afatinib, erlotinib, gefitinib, krizotinib i pemetreksed u liječenju karcinoma pluća ne-malih stanica (engl. Afatinib, erlotinib, gefitinib, crizotinib and pemetrexed in patients with nonsmall-cell lung cancer, NSCLC): Procjena zdravstvene tehnologije (engl. HTA), Broj 12/2015. Agencija za kvalitetu i akreditaciju u zdravstvu i socijalnoj skrbi, Služba za razvoj, istraživanje i zdravstvene tehnologije. Zagreb, svibanj 2015. http://aaz.hr/sites/default/files/HTA_12_2015.pdf (accessed January 11, 2016).Google Scholar
24. Dankó, D, Petrova, G. Health technology assessment in the Balkans: Opportunities for a balanced drug assessment system. Biotechnol Equip. 2014;28:1181–1189.Google Scholar
25. Sculpher, MJ, Pang, FS, Manca, A, et al. Generalisability in economic evaluation studies in healthcare: A review and case studies. Health Technol Assess. 2004;iii-iv:1–192.Google Scholar
26. Huić, M, Nachtnebel, A, Zechmeister, I, Pasternak, I, Wild, C. Collaboration in health technology assessment (EUnetHTA Joint Action, 2010–2012): Four case studies. Int J Technol Assess Health Care. 2013;12:1–8.Google Scholar
27. Kleijnen, S, Toenders, W, de Groot, F, et al. European collaboration on relative effectiveness assessments: What is needed to be successful? Health Policy. 2015;119:569–576.Google Scholar
28. Guegan, EW, Huić, M, Teljeur, C. EUnetHTA: Further steps towards European cooperation on health technology assessment. Int J Technol Assess Health Care. 2014;30:475–477.Google Scholar